• Home
  • News & Events

News & Events

Recent News


  • Vermillion Reports First Quarter 2019 Financial Results

    Vermillion Reports First Quarter 2019 Financial Results Conference Call scheduled for today, May 14th at 4:30 p.m. ET For the full press release please click here AUSTIN, Texas — May 14, 2019 — Vermillion, Inc. (NASDAQ: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today reported its financial results for the first quarter…

  • Vermillion Announces Acceptance of Publication: Ethnic Disparity Data Showing OVA1 (MIA) Superiority over CA125 and HE4 in Detecting Ovarian Cancer Risk

    Data showing detection improvements across all populations, with marked improvement in detecting ovarian malignancy risk in the African American population  Findings to be published in Biomarkers in Cancer Link to a pdf document can be found here AUSTIN, Texas, May 13, 2019 – Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women’s health company focused on gynecologic…

  • Vermillion Exhibits OVA1 Ethnic Disparity Performance Poster at the American Association for Cancer Research (AACR) Annual Meeting

    For link to the full press release click here AUSTIN, Texas, April 2, 2019 — Vermillion, Inc. (NASDAQ: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, is being represented at the 2019 American Association for Cancer Research Annual Meeting with a poster entitled “Ethnic Disparity in Detection of Ovarian Malignancy.” The poster was authored…

  • Vermillion Reports Fourth Quarter and Year-End 2018 Financial Results

    For a link to the full document click here   AUSTIN, Texas — March 28, 2018— Vermillion, Inc. (NASDAQ: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today reported its financial results for the fourth quarter and year ended December 31, 2018. “We are very pleased by the reception of our new generation…

  • Vermillion Announces Coverage by Cigna for OVA1®(MIA)

    Vermillion Announces Coverage by Cigna for OVA1®(MIA) 15 million covered lives will now have access to Vermillion’s innovative ovarian cancer risk assessment test For the link to the full press release click here AUSTIN, Texas, Jan. 15, 2019 — Vermillion, Inc. (NASDAQ: VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced that Cigna…

Upcoming Events


  • January 13–16, 2020

    San Francisco, CA

    J.P. Morgan Healthcare Conference

  • March 28–31, 2020

    Toronto, Canada

    Society of Gynecologic Oncology Annual Meeting

  • April 24–27, 2020

    Seattle, WA

    American College of Obstetricians and Gynecologists Annual Meeting

Investor Relations


  • Ashley R. Robinson

    LifeSci Advisors, LLC

    617-535-7742